Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.

doi:10.1016/j.xcrm.2024.101585

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.

Cell reports. Medicine - 18 Jun 2024

Montalban-Bravo Guillermo, Thongon Natthakan, Rodriguez-Sevilla Juan Jose, Ma Feiyang, Ganan-Gomez Irene, Yang Hui, Kim Yi June, Adema Vera, Wildeman Bethany, Tanaka Tomoyuki, Darbaniyan Faezeh, Al-Atrash Gheath, Dwyer Karen, Loghavi Sanam, Kanagal-Shamanna Rashmi, Song Xingzhi, Zhang Jianhua, Takahashi Koichi, Kantarjian Hagop, Garcia-Manero Guillermo, Colla Simona

Abstract excerpt

RAS pathway mutations, which are present in 30% of patients with chronic myelomonocytic leukemia (CMML) at diagnosis, confer a high risk of resistance to and progression after hypomethylating agent (HMA) therapy, the current standard of care for the disease. Here, using single-cell, multi-omics technologies, we seek to dissect the biological mechanisms underlying the initiation and progression of RAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blast Crisis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to DNA Methylation

Share to Hematopoietic Stem Cells

Share to Leukemia, Myelomonocytic, Chronic

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to NF-kappa B

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 38781960
DOI: 10.1016/j.xcrm.2024.101585
PMCID: PMC11228590

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.PMID 38781960Read ↗

Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in <i>RAS</i> -mutated chronic myelomonocytic leukemiaSemantic proximity Read ↗

Novel therapeutic targets for chronic myelomonocytic leukemia.Semantic proximity Read ↗

Emerging drugs for the treatment of chronic myelomonocytic leukemia.Semantic proximity Read ↗

Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.Semantic proximity Read ↗

Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovationsSemantic proximity Read ↗

Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment.Semantic proximity Read ↗

Evolving Understanding of Chronic Myelomonocytic Leukemia: Implications for Future Treatment Paradigms.Semantic proximity Read ↗

Chronic myelomonocytic leukemia without increased classical monocyte subsets exhibits a distinct genetic profile, including frequent CBL mutations.Semantic proximity Read ↗

How I diagnose and treat chronic myelomonocytic leukemia.Semantic proximity Read ↗

Genomic determinants of chronic myelomonocytic leukemia.Semantic proximity Read ↗

Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.Semantic proximity Read ↗

An arms‐race against resistance: leukemic stem cells and lineage plasticitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.